Evidence map›Paper›PMID 32884116›Full record

ArticleOncogene2020

RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma.

Eric Y Lian, Brandy D Hyndman, Serisha Moodley, Sarah M Maritan, Lois M Mulligan

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. HigherBiomolecules · 2021
    Article
  11. Hallmarks of RET and Co-occuring Genomic Alterations inMolecular cancer therapeutics · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Eric Y LianDivision of Cancer Biology and Genetics, Cancer Research Institute and Department of Pathology & Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.ORCID http://orcid.org/0000-0002-2147-5422
Brandy D HyndmanDivision of Cancer Biology and Genetics, Cancer Research Institute and Department of Pathology & Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.ORCID http://orcid.org/0000-0003-4096-0922
Serisha MoodleyDivision of Cancer Biology and Genetics, Cancer Research Institute and Department of Pathology & Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.
Sarah M MaritanDivision of Cancer Biology and Genetics, Cancer Research Institute and Department of Pathology & Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.ORCID http://orcid.org/0000-0002-9703-7429
Lois M MulliganDivision of Cancer Biology and Genetics, Cancer Research Institute and Department of Pathology & Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada. mulligal@queensu.ca.ORCID http://orcid.org/0000-0002-9308-8245
Queen's University · CA

Funding

CIHR MOP-142303
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a therapeutically challenging disease with poor survival rates, owing to late diagnosis and early dissemination. These tumors frequently undergo perineural invasion, spreading along nerves regionally and to distant sites. The RET receptor tyrosine kinase is implicated in increased aggressiveness, local invasion, and metastasis in multiple cancers, including PDAC. RET mediates directional motility and invasion towards sources of its neurotrophic factor ligands, suggesting that it may enhance perineural invasion of tumor cells towards nerves. RET is expressed as two main isoforms, RET9 and RET51, which differ in their protein interactions and oncogenic potentials, however, the contributions of RET isoforms to neural invasion have not been investigated. In this study, we generated total RET and isoform-specific knockdown PDAC cell lines and assessed the contributions of RET isoforms to PDAC invasive spread. Our data show that RET activity induces cell polarization and actin remodeling through activation of CDC42 and RHOA GTPases to promote directional motility in PDAC cells. Further, we show that RET interacts with the adaptor protein TKS5 to induce invadopodia formation, enhance matrix degradation and promote tumor cell invasion through a SRC and GRB2-dependent mechanism. Finally, we show that RET51 is the predominant isoform contributing to these RET-mediated invasive processes in PDAC. Together, our work suggests that RET expression in pancreatic cancers may enhance tumor aggressiveness by promoting perineural invasion, and that RET expression may be a valuable marker of invasiveness, and a potential therapeutic target in the treatment of these cancers.

Indexed as

Adaptor Proteins, Vesicular TransportCarcinoma, Pancreatic DuctalCell Line, TumorCell MovementCell PolarityCell ProliferationCoculture TechniquesGene Knockdown TechniquesHEK293 CellsHumansNeoplasm InvasivenessPancreatic NeoplasmsProtein IsoformsProto-Oncogene Proteins c-retrho GTP-Binding ProteinsSpheroids, CellularAdaptor Proteins, Vesicular TransportProtein IsoformsProto-Oncogene Proteins c-retRET protein, humanrho GTP-Binding ProteinsSH3PXD2A protein, humansrc-Family Kinases

Identifiers

PMID32884116
OpenAlexW3082262640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.